The research team, led by authors including Guangwei Zheng, Peiyuan Wang and Tao Xu, built their nanocarrier, dubbed cSiCe&ICG, through a lamellar micelle spiral self-assembly process conducted in a biphasic oil-water stratification system. In this elegant one-pot synthesis, the silicate precursor tetraethyl orthosilicate dissolved in cyclohexane sits atop an aqueous phase containing the surfactant template hexadecyltrimethylammonium p-toluenesulfonate and triethanolamine as a catalyst. Under continuous stirring, lamellar micelles co-assemble at the interface into helical, multi-shelled mesoporous silica nanospheres roughly 170 nanometers in diameter. The cerium precursor, added six hours into the reaction, hydrolyzes into cerium oxide nanogranules that anchor both to the silica surface and within the framework, giving a cerium-to-silicon weight ratio of 2:7. Transmission electron microscopy revealed that the resulting particles exist as mixtures of clockwise and counterclockwise helical configurations, with interlayer spacings of about 3 nanometers and outer gaps exceeding 10 nanometers, a texture that proved critical for what came next.

Chirality, the property of existing as mirror-image forms, is ubiquitous in biology, where amino acids and phospholipids occur almost exclusively in the L-configuration and sugars in the D-form. The researchers reasoned that importing chirality into an inorganic nanoreactor could confer advantages that symmetric particles lack. Their comparisons against a conventional dendritic mesoporous silica counterpart, mSiCe&ICG, bore this out repeatedly. The chiral channels promoted monomeric dispersion of the loaded ICG rather than the fluorescence-quenching J-aggregates that form in symmetric pores, and the spiral architecture with fewer open ends accelerated molecular motion. The practical consequence was striking: after 24 hours under ambient light, the NIR-II fluorescence of cSiCe&ICG was 21-fold stronger than free ICG, while the achiral mSiCe&ICG reached only 14-fold. The chiral particles also degraded faster in mildly acidic conditions, disintegrating within 24 hours at pH 6.5 while remaining intact at physiological pH 7.4, a built-in safety feature that confines drug release to the tumor microenvironment.

The imaging gains address a well-known weakness of ICG, the only NIR fluorophore in routine clinical use. Although ICG emits in both the first and second near-infrared windows, it suffers from rapid bloodstream clearance, poor tumor retention, strong binding to serum albumin, and rapid photodegradation under the very lasers used to excite it. Encapsulated within the chiral mesopores, ICG retained more than 90 percent of its initial fluorescence after 72 hours in serum with no detectable leakage, and the loading efficiency reached 20.61 percent. In tumor-bearing mice, the chiral probe painted a clear tumor outline from 6 to 12 hours after intravenous injection, while free ICG produced negligible tumor signal. Quantitative measurements of cerium ions by inductively coupled plasma optical emission spectroscopy confirmed far greater tumor accumulation for the chiral formulation, and the tumor-to-background ratio peaked at approximately 10.8 times that of free ICG at the 12-hour mark, which the team selected as the optimal imaging and treatment window.

The therapeutic half of the platform exploits the redox versatility of cerium, which shuttles between Ce4+ and Ce3+ oxidation states. X-ray photoelectron spectroscopy showed a Ce3+ to Ce4+ ratio of roughly 4:3, favorable for Fenton-like catalysis. In the acidic tumor milieu, the cerium oxide nanozymes decompose hydrogen peroxide into hydroxyl radicals while simultaneously depleting glutathione, the cell’s principal antioxidant, by more than 85 percent after 36 hours at pH 6.5. This dual action strips away the tumor’s chemical defenses and floods the cytoplasm with reactive oxygen species. The photothermal component then acts as an amplifier: under 808-nanometer laser irradiation, the ICG-loaded nanoreactor heated a 200 microgram per milliliter solution to 60.3 degrees Celsius in five minutes, compared with 47.9 degrees for free ICG and 30.5 degrees for saline, with a light-to-heat conversion efficiency of approximately 58.8 percent and stable performance across repeated laser cycles.

Cell culture experiments with MB49 bladder cancer cells demonstrated how heat and catalysis conspire. Confocal microscopy showed that cellular uptake of the chiral particles peaked at eight hours and significantly exceeded that of the achiral control, with the chiral probes entering cells through both caveolin- and clathrin-mediated endocytosis rather than the single caveolin pathway used by symmetric particles. When laser irradiation was added, intracellular reactive oxygen species, detected by the DCFH-DA probe, rose dramatically above every control group, and hydroxyphenyl fluorescein staining confirmed a surge of hydroxyl radicals. JC-1 staining revealed severe mitochondrial membrane depolarization in the treated cells, and flow cytometry quantified approximately 62.5 percent apoptotic cell death in the combined-treatment group. Notably, even at the highest tested concentration of 300 micrograms per milliliter, 93.8 percent of normal human umbilical vein endothelial cells remained viable, reflecting the particle’s dependence on acidic conditions for activation.

The surgical navigation experiments delivered perhaps the most clinically resonant results. Twelve hours after injection, NIR-II fluorescence clearly delineated tumor margins in mice with subcutaneous bladder tumors. Surgeons first removed the main tumor mass under white light, then scanned the surgical bed with the NIR-II system, which flagged residual fluorescent tissue that was subsequently resected. Histological examination found no remaining cancer cells in the fluorescence-guided group, whereas tumors removed under white light alone left residual tumor cells behind. Thirty days after surgery, bioluminescence imaging detected recurrence in every mouse operated under white light, but no signal in the fluorescence-guided group. Survival at 60 days reached 80 percent for the NIR-II-guided cohort compared with just 10 percent for the white-light group, a difference the authors attribute to the chiral probe’s superior tumor penetration, retention, and protein corona formation, which extended its blood circulation half-life to 11.7 hours versus 7.4 hours for the achiral version.

In the therapeutic efficacy study, mice receiving the full combination of cSiCe&ICG plus laser irradiation showed the strongest tumor regression over a 21-day treatment period, outperforming the achiral formulation and the cerium-only groups. Histological staining with hematoxylin and eosin, TUNEL, and Ki67 confirmed extensive tumor destruction, widespread apoptosis, and suppressed proliferation in the combination group. Biosafety assessments were encouraging: treated mice maintained stable body weights, blood chemistry and hematological indices stayed within healthy ranges, and cerium and silicon ions were almost completely cleared from the liver, spleen, and lungs within 28 days. Serum levels of inflammatory cytokines including IL-10, TNF-alpha, and IFN-gamma showed no significant fluctuations, and the particles’ rapid biodegradation under acidic conditions further limited off-target exposure.

The authors report that this represents the first facile fabrication of a chiral cerium oxide nanoreactor for precise, synergistic treatment of malignant tumors, and the design philosophy carries broader implications. By demonstrating that chirality can simultaneously enhance cellular uptake, fluorescence output, catalytic efficiency, and biodegradation, the study suggests that mirror-image engineering of inorganic nanomaterials is a powerful, largely untapped lever for cancer nanomedicine. The platform’s reliance on clinically accepted ICG, a straightforward one-pot synthesis, and tumor-triggered disassembly positions it favorably for translational development. Considerable work remains before such nanoreactors reach the operating room, including larger animal models, orthotopic bladder tumors, and formal toxicity studies, but the convergence of image-guided surgery with photothermally reinforced chemodynamic therapy offers a compelling template for tackling the residual disease that drives bladder cancer recurrence.

Subject of Research: A chiral cerium-doped mesoporous silica nanoreactor for fluorescence-guided surgery and photothermal-chemodynamic therapy of bladder cancer

Article Title: Chiral cerium doped nanoreactor-mediated bladder carcinoma reinforced ablation via fluorescence imaging navigated surgery along with photothermal strengthened ROS storm

Article References: Zheng, G., Wang, A., Du, Y., Qin, C., Song, Y., Wu, J., Luo, X., Liu, X., Wang, P., & Xu, T. (2026). Chiral cerium doped nanoreactor-mediated bladder carcinoma reinforced ablation via fluorescence imaging navigated surgery along with photothermal strengthened ROS storm. Materials Today Bio, 41, Article 103746. https://doi.org/10.1016/j.mtbio.2026.103746

Image Credits: AI Generated

DOI: Not provided

Keywords: bladder cancer, chiral nanoparticles, cerium oxide, mesoporous silica, indocyanine green, NIR-II fluorescence imaging, photothermal therapy, chemodynamic therapy, reactive oxygen species, image-guided surgery, nanoreactor, tumor microenvironment

The technique relies on indocyanine green, or ICG, a fluorescent tracer that has been approved for clinical use for decades. When injected into a vein, ICG binds to plasma proteins and stays within the bloodstream. Illuminated by near-infrared light, it emits a fluorescent signal that can be captured by a specialized camera system, allowing surgeons to watch blood perfusion unfold across the surface of an organ in real time. Because near-infrared light penetrates tissue more deeply than visible light and generates little background interference, the resulting images can reveal the boundary between tissue that is being fed by blood and tissue that has lost its supply.

In the study, published in BMC Pediatrics, a surgical team led by Li Tao, Xu Cao, and corresponding author Shu Dai applied this technology to ten children who underwent emergency surgery for testicular rupture between July 2023 and December 2025. During each operation, the surgeons injected ICG intravenously at a dose of 0.2 milligrams per kilogram of body weight and then used a near-infrared fluorescence imaging system to perform real-time angiography of the exposed testicle. The goal was to delineate, on the operating table and within minutes, the exact boundary between nonperfused tissue and tissue that was still receiving blood.

The results were strikingly consistent. In all ten patients, the fluorescence imaging clearly delineated the boundary between areas where fluorescence could be detected and areas where it could not. Those findings were incorporated into the surgeons’ overall intraoperative assessment and used to guide selective excision of tissue considered nonviable. Once the dead tissue had been removed, the team repaired the resulting defect using either sutures of the tunica albuginea, the tough fibrous capsule surrounding the testicle, or a patch of tunica vaginalis, the membrane that normally cushions the organ within the scrotum.

Follow-up examinations offered cautious encouragement. With a median follow-up of ten months, ranging from three to 32 months, all of the repaired testes showed regular morphology and homogeneous echogenicity on grayscale ultrasound, an indication that the tissue architecture had healed without the scarring or irregularity that often follows significant testicular injury. Color Doppler flow imaging, the standard ultrasound technique for visualizing blood flow, demonstrated normal blood flow signals in every case. No postoperative complications were documented in the available clinical records during the follow-up period.

The clinical stakes of this problem are considerable. Testicular rupture, in which blunt trauma tears the tunica albuginea and extrudes the delicate seminiferous tubules inside, is one of the most time-sensitive emergencies in pediatric urology. The viability of the gonad depends heavily on how quickly blood flow is restored and how accurately the surgeon judges which tissue can survive. Traditional assessment relies on visual inspection of color, texture, and bleeding at the cut edges, supplemented by preoperative ultrasound. These cues are notoriously subjective, and both errors carry lasting consequences: leaving devitalized tissue increases the risk of necrosis and atrophy, while over-resection removes germ cells that might otherwise have contributed to preserved fertility and hormone production.

ICG fluorescence imaging addresses that subjectivity directly by giving surgeons an objective, dynamic map of perfusion. The physics behind the technique is elegant. ICG absorbs light in the near-infrared range, around 800 nanometers, and re-emits it at slightly longer wavelengths. Because hemoglobin and water absorb relatively little light in this window, the fluorescence signal can be detected from tissue several millimeters to a centimeter beneath the surface, and the contrast between perfused and nonperfused regions appears within seconds of injection. In other surgical specialties, from colorectal anastomosis to reconstructive flap surgery, this real-time perfusion mapping has already changed intraoperative decision-making, and the Suzhou team’s work extends that logic to a delicate pediatric organ where every cubic millimeter of viable tissue matters.

The authors are careful to frame their findings as preliminary. This was a pilot feasibility study with only ten patients, conducted as a retrospective review of children who had already been treated under an approved new clinical technology application. The ethical approvals covered both the clinical use of ICG during testicular rupture surgery, granted in 2023, and the retrospective analysis of the resulting records, approved under number 2026CS087 before any data were abstracted. Because the study lacked a control group, it cannot yet demonstrate that ICG guidance improves long-term outcomes compared with conventional surgical judgment alone. The uniformly good results could reflect the imaging technique, careful patient selection, skilled surgery, or simply the natural history of promptly treated rupture. The authors explicitly state that their findings require validation in larger, controlled studies to determine the technique’s impact on long-term outcomes.

Nevertheless, the safety profile observed in this small cohort is reassuring. ICG has a long track record of clinical use, with adverse reactions generally rare and mild, and no adverse events were observed in these ten children. The dose used, 0.2 milligrams per kilogram, is modest, and the imaging procedure adds only a few minutes to an emergency operation, a meaningful consideration when ischemia time is a critical determinant of organ survival. For pediatric urologists, the appeal of the technique lies precisely in this combination of speed, simplicity, and visual clarity: a single injection and a camera turn an invisible physiological variable, blood flow, into an immediately interpretable image on the operating room monitor.

The broader significance of the study extends beyond urology. It represents part of a growing movement in surgery toward fluorescence-guided decision-making, in which molecular tracers and optical imaging replace guesswork with measurable signals. If larger trials confirm the Suzhou results, ICG imaging could become a standard adjunct in pediatric scrotal trauma, helping surgeons preserve organs that would once have been lost. For the children in this study, the glowing green map on the operating room monitor appears to have done exactly what such technology promises: it showed the surgeons where life remained in damaged tissue, and it helped them keep it. Whether that promise holds across hundreds of patients will be the question that future controlled studies must answer, but the first step has now been taken, and it was taken in glowing green.

Subject of Research: Intraoperative indocyanine green fluorescence imaging to assess tissue perfusion during pediatric testicular rupture surgery

Article Title: Indocyanine green fluorescence imaging for intraoperative assessment of tissue perfusion in pediatric testicular rupture: a pilot feasibility study

Article References: Tao, L., Cao, X., Huang, M., Wang, T., Zhang, L., Xia, H., Fu, M., Zhou, Y., Zhang, T., Yan, X., & Dai, S. (2026). Indocyanine green fluorescence imaging for intraoperative assessment of tissue perfusion in pediatric testicular rupture: a pilot feasibility study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07846-8

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07846-8

Keywords: indocyanine green, fluorescence imaging, testicular rupture, pediatric surgery, tissue perfusion, near-infrared imaging, intraoperative assessment, urology, pilot study, organ preservation, surgical imaging, BMC Pediatrics

The sentinel lymph node concept rests on a simple anatomical insight: when a tumour begins to spread, cancer cells do not scatter randomly through the lymphatic system. Instead, they travel first to one or a few nearby lymph nodes, the so-called sentinel nodes, which act as the initial filters on the drainage pathway. If surgeons can identify and remove precisely those nodes, pathologists can examine them closely for metastatic cells, and the wider lymphatic basin can be left intact when they are clean. This spares patients the morbidity of extensive lymph node dissection, which in the pelvis and para-aortic region can include lymphedema, lymphoceles, vascular injury, and prolonged recovery. Sentinel node biopsy has transformed the management of breast cancer and melanoma, and it is increasingly applied in endometrial and cervical cancer as well.

Ovarian cancer, however, has proven a harder target. The lymphatic drainage of the ovary is unusually complex, following the ovarian vessels upward along the infundibulopelvic ligament toward para-aortic nodes high in the retroperitoneum, while parallel pathways drain through the broad ligament to pelvic nodes along the iliac vessels. This dual drainage means that sentinel nodes in ovarian cancer can appear on both sides of the body and at considerable distance from the tumour, making reliable identification technically demanding. Moreover, most patients with ovarian cancer are diagnosed at advanced stages, when the disease has already spread beyond the ovary and full surgical staging with systematic lymphadenectomy is standard. It is in the smaller group of patients with apparently early-stage disease, where the distinction between stage I and stage III hinges on whether lymph nodes contain microscopic deposits, that a minimally invasive sentinel node approach would be most valuable.

The standard technique for sentinel node detection in ovarian cancer combines a radioactive tracer, technetium-99m radiocolloid, with a visual agent such as blue dye or indocyanine green, a fluorescent compound that glows under near-infrared light. The radiocolloid is injected near the tumour, drains to the sentinel nodes, and is located intraoperatively with a handheld gamma probe that clicks as it approaches the radioactive signal. Studies have shown this combination to be feasible, but each component carries practical drawbacks. Technetium-99m requires coordination with a nuclear medicine department, involves radiation exposure for patients and staff, and is subject to regulatory and logistical constraints that limit its availability in many hospitals, particularly in low-resource settings. Blue dye carries a small risk of anaphylaxis and can permanently tattoo the skin, while indocyanine green requires specialized near-infrared imaging equipment that works well through tissue only to a limited depth.

These limitations are especially acute in ovarian cancer surgery, which is typically performed by laparotomy, a large open abdominal incision, rather than by minimally invasive laparoscopy. Fluorescent tracers such as indocyanine green excel in laparoscopic procedures, where the camera system integrates the infrared imaging, but in an open surgical field the fluorescence can be difficult to visualize under standard operating room lighting, and the signal may be washed out by ambient light or obscured by tissue and blood. A tracer that could be detected with a simple handheld probe, without radiation and without dependence on optical conditions, would fit the open-surgery environment far more naturally. This is the gap that Magtrace is designed to fill.

Magtrace is a suspension of superparamagnetic iron oxide particles, micrometre-scale carriers loaded with even smaller iron oxide cores. Once injected into the tissue near the tumour, the particles are taken up by lymphatic vessels and carried to the regional lymph nodes, where they accumulate and impart a characteristic brown discoloration that surgeons can see directly. More importantly, the particles distort a local magnetic field in a way that a handheld device called the Sentimag probe can detect. The probe, which resembles a modified magnetometer, is passed over the surgical field and produces an audible and visual signal whose strength increases as it nears the magnetized tissue, allowing the surgeon to home in on the sentinel node much as a gamma probe tracks radioactivity. Because the magnetic signal is not attenuated by tissue in the way light is, and because it involves no ionizing radiation, the technique can in principle be used in any operating room without nuclear medicine support.

In the Maastricht study, the researchers injected both Magtrace and technetium-99m into the same anatomical structures, the ligamentum ovarii proprium, which connects the ovary to the uterus, and the infundibulopelvic ligament or its stumps, through which the ovarian vessels run toward the para-aortic region. Injecting both tracers at the same sites allowed a direct head-to-head comparison: after an interval of at least fifteen minutes, the surgical team located sentinel nodes using the Sentimag probe for the magnetic tracer and a gamma probe for the radiocolloid. The dual-tracer design is a common strategy in pilot studies of new tracers, because it lets investigators measure how often the new agent finds the same nodes as the established one, and whether it finds any nodes the standard technique misses.

The patient cohort illustrates the practical complexities of studying early ovarian cancer. Of the sixteen patients enrolled, ten actually received the tracer injections, nine during primary surgery for suspected ovarian cancer and one during secondary staging after a previous tumour resection had already confirmed the disease. Among the nine primary surgery patients, frozen-section analysis, the rapid microscopic examination of tissue performed while the patient is still on the operating table, revealed that six actually had benign or borderline tumours rather than invasive carcinoma, so the sentinel node procedure was not clinically relevant for them. That left three patients with confirmed epithelial ovarian cancer undergoing primary staging, and in all three the procedure succeeded, with at least one sentinel node identified using Magtrace. In the single patient who underwent mapping during secondary staging, the procedure was unsuccessful, a failure the authors note may relate to the altered anatomy and scar tissue left by the prior surgery, which can disrupt lymphatic drainage pathways.

The investigators conclude that Magtrace injection shows promise for sentinel node detection in epithelial ovarian cancer, while emphasizing that larger studies are needed to confirm its value. That caution is warranted. With only three successful primary staging cases, the study cannot establish detection rates, sensitivity, or false-negative rates, the metrics that ultimately determine whether a sentinel node technique is safe to rely on in clinical practice. The high proportion of benign frozen-section results also highlights a recurring challenge in this field: preoperative imaging often cannot reliably distinguish early ovarian cancer from benign masses, so trials of staging techniques must enroll generously and expect a substantial fraction of participants to fall outside the target diagnosis. The single failure in secondary staging likewise suggests that the technique’s role may be limited to primary surgery, at least initially.

Nevertheless, the study points toward a plausible future in which ovarian cancer staging becomes less burdensome. A magnetic tracer that works in open surgery, requires no radioactive material, and leaves a visible brown mark on the sentinel nodes could make sentinel node biopsy accessible to surgical teams worldwide who lack nuclear medicine infrastructure, and could simplify logistics for centres that do. Before that future arrives, the technique will need validation in larger prospective cohorts, ideally comparing Magtrace directly against the established radiocolloid and fluorescence combinations and following patients long enough to confirm that a negative sentinel node truly predicts the absence of regional metastases. For now, the Maastricht pilot offers an early but encouraging signal that the magnetic approach, so successful in breast cancer, may find a place in one of gynaecologic oncology’s most technically stubborn frontiers.

Subject of Research: Sentinel lymph node detection using the magnetic tracer Magtrace in early-stage epithelial ovarian cancer

Article Title: Magtrace as tracer for sentinel lymph node detection in early stage epithelial ovarian cancer: a pilot study

Article References: Laven, P., van der Pol, J. A. J., Slangen, B. F. M., Kruitwagen, R. F. P. M., & Lambrechts, S. (2026). Magtrace as tracer for sentinel lymph node detection in early stage epithelial ovarian cancer: a pilot study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02297-2

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02297-2

Keywords: ovarian cancer, sentinel lymph node, Magtrace, magnetic tracer, superparamagnetic iron oxide, Sentimag, technetium-99m, indocyanine green, laparotomy, surgical staging, gynaecologic oncology, pilot study

The commentary responds to a short communication by Hamm and colleagues describing computed tomography-guided percutaneous marking of lung nodules using two well-established agents: patent blue V, a visible dye, and indocyanine green, a fluorescent tracer that glows under near-infrared light. The German team also explored indocyanine green-soaked coils, small metallic spirals drenched in the fluorescent dye before deployment. In their reported series, all patients underwent complete resection without conversion to open surgery, a result the commentary authors describe as underscoring the technical reliability of the approach. What makes the technique attractive, they note, is its accessibility and workflow flexibility: the marking is performed percutaneously in the radiology suite, avoiding rigid transpleural devices that must stay in place until resection, and eliminating the need for intraoperative fluoroscopy altogether.

That last point matters more than it might first appear. Robotic-assisted thoracic surgery has transformed minimally invasive lung resection, offering articulated instruments, high-definition three-dimensional vision, and steady precision within a confined chest cavity. But robotic operating environments are notoriously unfriendly to techniques that require a fluoroscope to be wheeled in mid-operation. Hybrid operating rooms equipped with integrated imaging remain scarce and expensive, particularly outside major academic centres. A localisation strategy that relies on preoperative computed tomography guidance and then hands off to near-infrared fluorescence, which integrates seamlessly into robotic camera platforms, preserves operative ergonomics and could allow hospitals without hybrid theatres to offer minimally invasive sublobar resection to their patients. In this sense, the commentary frames computed tomography-guided fluorescence as a platform technology reinforcing the expanding role of interventional radiology in precision thoracic oncology.

To understand where the field is heading, the authors propose a generational framework for pulmonary localisation strategies. The first generation was hook-wire localisation, in which a thin wire with a hooked tip is placed into or adjacent to the nodule under imaging guidance. Wires are effective but carry well-known drawbacks: they can displace, they puncture the pleura and can cause pneumothorax, and the rigid external component must be managed carefully until the surgeon removes it. The second generation was percutaneous dye injection, simple and cheap, but vulnerable to two failure modes: dyes diffuse through the soft lung parenchyma and they fade over time, so the target zone a surgeon sees may no longer correspond to where the dye was originally placed. The third generation introduced coil-assisted fluorescence, in which a metallic coil provides mechanical containment for the fluorescent dye, improving durability and visibility.

It is the fourth generation, still emerging, that excites the commentary’s authors most: stabilised fluorescent matrices designed to optimise spatial fidelity. The central insight is that diffusion control is not a minor technical detail but the very heart of localisation accuracy. When liquid dye is injected into lung tissue, it spreads laterally through the interstitium, creating a fluorescent zone that grows and blurs over time. Visibility without spatial fidelity, the authors warn, risks misleading surgical guidance. In a lobectomy, where the entire lobe is removed, a few millimetres of dye drift are inconsequential. But in a sublobar resection, a segmentectomy or wedge resection intended to preserve as much healthy lung as possible, margin geometry is everything. If the fluorescent cloud has migrated, the surgeon may resect around the wrong centre, compromising the distance between the tumour edge and the cut margin.

The stakes of margin integrity have been raised sharply by randomised evidence. The Japanese JCOG0802/WJOG4607L trial, a multicentre phase 3 study published in The Lancet in 2022, demonstrated that segmentectomy is non-inferior to lobectomy for small peripheral non-small-cell lung cancer, validating lung-preserving surgery for selected early-stage patients. That victory for tissue-sparing oncology, however, makes the localisation problem more acute rather than less. When the goal shifts from removing an entire lobe to carving out a precise wedge around a ten-millimetre lesion, the surgeon depends absolutely on the fidelity of whatever marker was placed the day before. Margin distance and local recurrence become the decisive metrics, and any localisation technique that cannot guarantee spatial accuracy becomes the weak link in an otherwise elegant chain.

This is why the commentary insists that future localisation research be framed by oncologic endpoints rather than technical success alone. Viana and Nunes call for systematic reporting of lesion depth, minimal margin distance, and longitudinal local recurrence in every study of nodule marking. Complete resection rates, while reassuring, are a blunt instrument; a resection can be complete yet carry a margin so narrow that recurrence risk rises. They also urge multicentre prospective validation within robotic workflows, recognising that single-centre feasibility studies, however encouraging, cannot establish whether a technique performs consistently across different operators, scanner platforms, and patient anatomies. Whether molecular stabilisation of fluorescent dyes translates into superior oncologic precision, they acknowledge, requires exactly this kind of prospective evaluation, but the conceptual evolution is notable.

The stabilised matrix concept represents a genuinely biochemical approach to a problem that previous generations attacked mechanically. Rather than containing dye with a coil or accepting its diffusion as inevitable, these formulations modulate dye distribution at the injection site itself, reducing lateral spread and potentially improving margin predictability. The commentary’s authors have direct experience in this territory: they previously published a technical note on computed tomography-guided dual-fluorescent marking for robotic sublobar resection covering 84 consecutive cases, work cited in their commentary as part of the field’s progression. Their argument is that these four generations, hook-wires, dye injections, coil-assisted fluorescence, and stabilised matrices, should be understood not as competitors but as iterative refinements, each responding to a clearly identified limitation of its predecessor.

For readers wondering why this seemingly niche surgical debate deserves broader attention, the answer lies in the convergence of three trends that are reshaping cancer care worldwide. Screening programmes are expanding, which means more small nodules will be found and more of them will be operated on. Robotic platforms are proliferating, which means more of those operations will be performed with instruments that cannot palpate a lesion hidden in deflated lung tissue. And lung-preserving resection is gaining evidence-based legitimacy, which means the precision demands on localisation will only intensify. The commentary’s closing line captures the moment succinctly: if feasibility has defined the past decade of computed tomography-guided localisation, precision will define the next. What began as a practical question of how to mark a spot in the lung is maturing into a rigorous discipline of spatial oncology, where the biochemistry of a dye, the geometry of a surgical margin, and the long-term risk of cancer recurrence are inseparably linked.

There are, of course, caveats that the commentary itself makes explicit. The heterogeneity of marking techniques currently in use, spanning simple dye injection and coil-assisted fluorescence, reflects an important developmental phase but may limit standardisation, making head-to-head comparisons difficult. The stabilised fluorescent matrices remain conceptually promising rather than prospectively proven, and their advantage over coil containment must be demonstrated in controlled studies. Nor does the commentary claim that any single technique is universally superior; instead, it offers a roadmap for how the field should evaluate its options. For a specialty in which a few millimetres of tissue can determine whether a patient keeps half a lung or loses a whole one, that shift in standards, from visible to verifiable, from feasible to faithful, may prove to be the most consequential development in thoracic surgical oncology this decade.

Subject of Research: Computed tomography-guided fluorescent localisation of small pulmonary nodules for robotic thoracic surgery

Article Title: Evolving generations of computed tomography-guided lung nodule localisation toward stabilised fluorescent precision in robotic thoracic oncology

Article References: Viana, P. C. C., & Nunes, T. F. (2026). Evolving generations of computed tomography-guided lung nodule localisation toward stabilised fluorescent precision in robotic thoracic oncology. CVIR Oncology, 2(1), Article 31. https://doi.org/10.1007/s44343-026-00036-4

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00036-4

Keywords: lung nodule localisation, computed tomography guidance, indocyanine green, patent blue V, fluorescence imaging, robotic thoracic surgery, sublobar resection, segmentectomy, surgical margins, interventional radiology, precision oncology, stabilised fluorescent matrices

The report, led by interventional radiologist Charlie A. Hamm and colleagues, is framed as a technical roadmap rather than a large trial, but its results are striking in their consistency. Eleven patients, four women and seven men ranging in age from 34 to 77, underwent CT-guided dye-based marking of twelve lung nodules before minimally invasive, lung-sparing resection. The median nodule diameter was just 8.5 millimeters. Every single marking procedure was technically successful, every lesion was completely resected, and no operation had to be converted to open surgery or an entire lobectomy because the surgeon could not find the target. Seven of the twelve lesions turned out to be malignant, underscoring how much rides on getting the localization right.

The clinical backdrop explains why this matters. Randomized screening trials such as the Dutch-Belgian NELSON study showed that volume-based CT screening reduces lung cancer mortality, and more recent cohort work like the SUMMIT study has confirmed that the majority of screen-detected cancers are diagnosed at stage I or II, when surgery is the primary treatment. That shift has pushed thoracic surgeons toward sublobar resection, removing a wedge of lung or a single segment rather than the whole lobe, to preserve as much healthy parenchyma as possible. But the smaller the lesion and the more tissue-sparing the operation, the more critical it becomes to know exactly where the target sits before the first incision is made.

The traditional answer has been the hook-wire, a thin barbed wire placed through the chest wall into or next to the nodule on the morning of surgery. Hook-wires work, but they come with real drawbacks. They typically force same-day scheduling of two procedures, they can dislodge or migrate before the surgeon reaches them, and a rigid wire protruding through the pleura is uncomfortable and potentially hazardous for the patient, who must be transported carefully to avoid tearing lung tissue. The Berlin team’s dye-based approach eliminates the transpleural hardware entirely, which the authors note has been reported to cause less patient discomfort and stress and reduces the risk of marker displacement.

The first of the two dye techniques relies on patent blue V, a synthetic triphenylmethane dye that has long been used to trace lymphatic drainage in breast surgery and melanoma staging. It is water-soluble, renally excreted, and has a low toxicity profile, with allergic reactions occurring in fewer than one percent of patients. Under CT-fluoroscopic guidance, the radiologist advances a fine 22-gauge Chiba needle until its tip sits immediately adjacent to the nodule, deliberately avoiding puncture of the lesion itself, which reduces the theoretical risk of tumor seeding along the needle track and avoids compromising the pathology specimen. Then 0.1 to 0.4 milliliters of dye is injected through a small Luer-lock syringe, and the needle is withdrawn promptly without a saline flush, which would dilute the dye and could tattoo the skin along the exit path.

What happens next is a matter of physics and anatomy. The dye diffuses through the terminal vascular bed of the lung and reaches the pleural surface, where it creates a sharply demarcated blue patch that tells the surgeon precisely where the resection margin should fall. If the lesion lies more than three centimeters beneath the pleura, the dye is injected in increments as the needle is withdrawn, leaving a stained tract running from the nodule toward the chest wall. Because patent blue V gradually disperses into the bloodstream and pleural fluid, the color fades within hours, so surgery must be scheduled the same day, ideally within three hours of the marking. In the Berlin series, the five patients who received patent blue V injections had a median marking time of just seven minutes.

The second technique solves the fading problem with indocyanine green, or ICG, a tricarbocyanine fluorescent dye that binds readily to tissue proteins and glows bright emerald green when excited by near-infrared light. Injected alone, ICG diffuses more slowly than patent blue V and can remain visible in lung tissue for up to six days, a finding documented in prior experimental work. More importantly, near-infrared light penetrates soft tissue far better than visible light, so a fluorescence camera in the operating room can detect the glowing signal from millimeters to several centimeters beneath the pleural surface, effectively letting the surgical team see through the lung’s outer rim to a depth of roughly three centimeters. The six patients in the series who received ICG-based marking had a median procedure time of 16.5 minutes.

The most innovative variant described in the report goes one step further: instead of injecting liquid dye that will eventually disperse, the team deploys a tiny embolization coil soaked in ICG. The preparation is meticulous. ICG is mixed with ten milliliters of sterile water, and two to three milliliters of the solution are used to slowly flush the coil introducer outside the patient to prevent premature deployment. The markers are Tornado-type coils measuring 0.035 inches in diameter and 7 to 8 millimeters in length. After percutaneous puncture with an 18-gauge coaxial needle, the coil is advanced with the stiff end of a guidewire and deployed under CT-fluoroscopy immediately adjacent to the lesion, with care taken not to push it too far past the target. The coil acts as a physical scaffold that holds the dye in place, and because the fluorescence persists for days, surgery can be scheduled up to thirteen days after marking, giving hospitals valuable flexibility when operating rooms are crowded or schedules shift unexpectedly.

Safety data from the series align with the broader literature. Only one complication occurred, an asymptomatic pneumothorax during needle puncture that was managed conservatively without any intervention, consistent with reported pneumothorax rates of around six percent for CT-guided ICG injection in a retrospective analysis of 471 patients. The authors do caution that coil placement requires a larger 18-gauge needle than pure dye injection, which may influence complication rates. Prior studies have reported technical success rates above 98 percent for CT-guided dye injection and 100 percent for bronchoscopy-guided ICG-coil placement, and the addition of preoperative markings has been shown in other reports to drive conversion rates to open surgery close to zero.

What makes the Berlin report notable is the delivery route. ICG-soaked coil marking had previously been described through bronchoscopy, a technique that requires general anesthesia and specialized endoscopic equipment, and only recently through a percutaneous approach. The CT-guided percutaneous route can be performed in an outpatient workflow under local anesthesia alone, making it less resource-intensive and easier to slot into a busy hospital schedule. The authors emphasize that the technique is ultimately a story about multidisciplinary collaboration: the tumor board decides the patient needs lung-sparing surgery, the interventional radiologist plants the beacon, and the thoracic surgeon follows the glow. As robotic-assisted and uniportal thoracoscopic surgery become more common and screening programs continue to surface ever-smaller nodules, dye-based marking may become a routine bridge between the radiology suite and the operating room, turning invisible targets into ones a surgeon cannot miss.

Subject of Research: CT-guided preoperative dye-based marking of small lung nodules for minimally invasive surgical resection

Article Title: CT-guided percutaneous marking of lung nodules using patent blue V and indocyanine green

Article References: Hamm, C. A., Elsner, A., Fehrenbach, U., Savic, L. J., Bawaadam, H., Collettini, F., Neudecker, J., Gebauer, B., Rückert, J., & Auer, T. A. (2026). CT-guided percutaneous marking of lung nodules using patent blue V and indocyanine green. CVIR Oncology, 2(1), Article 2. https://doi.org/10.1007/s44343-026-00031-9

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00031-9

Keywords: lung nodules, interventional radiology, indocyanine green, patent blue V, CT guidance, thoracic surgery, fluorescence imaging, preoperative localization, lung cancer screening, video-assisted thoracoscopic surgery, fiducial coils, lung-sparing resection

The centerpiece of the strategy is lactate, a molecule that sits at the heart of tumor metabolism. Cancer cells favor glycolysis even in the presence of oxygen, a phenomenon known as the Warburg effect, and the resulting lactate accumulation acidifies the tumor microenvironment, fuels new blood vessel growth through HIF-1α/VEGF signaling, recruits immunosuppressive cells, and even modifies key proteins such as p53 and MRE11 through a recently discovered epigenetic process called lactylation. By targeting lactate directly, the researchers sought to undermine the tumor’s energy supply and reverse the microenvironmental features that promote resistance and malignant progression.

The vehicle for this attack is a hollow mesoporous manganese dioxide nanoparticle, or HMnO₂, whose high surface area and large pore volume allow it to carry both an enzyme and a light-sensitive drug. The enzyme, lactate oxidase or LOX, converts lactate into pyruvate and hydrogen peroxide; the manganese dioxide carrier then decomposes that hydrogen peroxide into oxygen, which in turn sustains further lactate oxidation. This closed loop, the researchers explain, is self-sustaining: the enzyme consumes lactate and oxygen, generates hydrogen peroxide, and the carrier recycles that peroxide back into the oxygen the enzyme needs. The cycle continuously drains the tumor’s metabolic fuel, simultaneously raising oxygen levels, lowering local pH, and starving cancer cells.

The catalytic cycle was verified in a series of in vitro experiments. In the presence of lactate, LOX alone generated 50.58 µM of hydrogen peroxide, but the full HILA nanoparticle produced 4.25 times more, demonstrating that the manganese carrier amplifies the enzymatic reaction by regenerating oxygen in situ. Whereas free LOX rapidly exhausted dissolved oxygen in solution, HILA’s oxygen consumption declined only gradually, confirming that the carrier compensates for the enzyme’s oxygen appetite. The nanoparticles also proved to be responsive triggers: they degraded more readily in acidic, glutathione-rich conditions characteristic of tumors, releasing their indocyanine green payload in a pH-, glutathione-, peroxide-, and heat-dependent fashion, with near-infrared irradiation further accelerating drug liberation.

That payload, indocyanine green, is an FDA-approved near-infrared dye already used for fluorescence navigation in colorectal surgery. It can simultaneously mediate photodynamic therapy by generating singlet oxygen and photothermal therapy by converting light into heat. Yet its clinical promise has been hampered by poor stability, weak tumor targeting, and the hypoxic nature of tumors, which starves photodynamic therapy of the oxygen it needs. HILA addresses all three limitations at once. The oxygen regenerated by the catalytic cycle keeps singlet oxygen production running, the photothermal effect speeds catalytic kinetics, and the released manganese ions perform a Fenton-like reaction that churns out lethal hydroxyl radicals for chemodynamic therapy.

The photothermal measurements were striking. Under 780-nanometer irradiation, HILA achieved a temperature rise of 22.80 °C, exceeding free indocyanine green, and its photothermal conversion efficiency reached 33.83 percent—competitive with black phosphorus and gold-based agents while offering the clinical advantage of biodegradable, clinically vetted components. In lactate-enriched conditions mimicking the tumor microenvironment, HILA reached an even higher terminal temperature of 42.25 °C, because the catalytic cycle’s oxygen supply prevents the hypoxia-induced self-quenching that ordinarily degrades the dye’s performance. Its singlet oxygen quantum yield was approximately 8.9 times higher than free indocyanine green.

Tumor targeting came from a hyaluronic acid coating on the nanoparticle surface, which binds the CD44 receptors abundant on colon cancer cells. Fluorescence microscopy and flow cytometry showed that pretreating cells with free hyaluronic acid to block CD44 significantly reduced uptake, confirming the mechanism. In mice bearing CT26 colon tumors, HILA accumulated progressively in tumor tissue within eight hours of injection and persisted at high levels at 24 hours, while free indocyanine green faded rapidly. Infrared thermal imaging under laser exposure showed HILA-treated tumors heating by roughly 10 °C, the strongest photothermal response among the tested formulations, and ex vivo imaging confirmed selective tumor accumulation.

The therapy’s biological punch was documented in detail. In CT26 cells, HILA depleted intracellular lactate by roughly 60 percent under irradiation and suppressed cell migration from 50.30 percent closure in controls to 19.92 percent at 24 hours. Quantifying each modality’s contribution, the researchers found that in the dark, chemodynamic therapy accounted for 59.7 percent of the killing and starvation for 40.3 percent; under laser irradiation, phototherapy dominated at 72.6 percent, with chemodynamic and starvation effects acting as adjuvants. HILA also collapsed the cells’ antioxidant defenses, cutting glutathione levels by about 75 percent and elevating oxidized glutathione, thereby unleashing a lethal storm of reactive oxygen species from combined photodynamic, photothermal, and chemodynamic sources.

In vivo results sealed the case. Mice treated intravenously with HILA followed by near-infrared irradiation showed near-complete tumor suppression, the lowest excised tumor weights, extensive apoptosis on TUNEL staining, and sharply reduced Ki67 proliferation markers. Hemolysis assays showed less than five percent hemolysis, blood biochemistry revealed no systemic toxicity fourteen days after administration, histology of major organs showed no damage, and body weights remained stable throughout treatment. Pharmacokinetic profiling showed prolonged circulation half-life and mean residence time compared with free drug, extending bioavailability and retention.

The authors describe HILA as a self-amplifying cascade in which lactate depletion, oxygen generation, acidification, glutathione consumption, and light-triggered phototherapy reinforce one another in a positive feedback loop, remodeling the tumor microenvironment while eradicating the cancer within it. By relying on biodegradable, FDA-adjacent components—an approved imaging dye, an enzyme, manganese dioxide, and hyaluronic acid—the platform offers what the researchers call a clinically translatable blueprint for minimally invasive, precision cancer therapy, one that turns the tumor’s own metabolic exhaust into the engine of its destruction.

Subject of Research: A self-sustaining lactate-depleting nanoplatform for multimodal colon cancer therapy

Article Title: Self‐Sustaining Lactate Depletion Nanoplatform Remodels Tumor Microenvironment and Augments Synergistic Photodynamic/Photothermal/Chemodynamic/Starvation Therapy for Eradication of Colon Cancer

Article References: Wang, Y.-E., Zhao, S., Wu, W., Duan, Z., Li, Y., Zeng, X., Hong, L., Chen, Y., Tao, L., Zeng, K., Xiao, C., & Shen, X. (2026). Self‐Sustaining Lactate Depletion Nanoplatform Remodels Tumor Microenvironment and Augments Synergistic Photodynamic/Photothermal/Chemodynamic/Starvation Therapy for Eradication of Colon Cancer. Advanced Science, 13(53), Article e76367. https://doi.org/10.1002/advs.76367

Image Credits: AI Generated

DOI: 10.1002/advs.76367

Keywords: colon cancer, lactate oxidase, manganese dioxide nanoparticles, tumor microenvironment, photodynamic therapy, photothermal therapy, chemodynamic therapy, starvation therapy, indocyanine green, hyaluronic acid targeting, Warburg effect, nanomedicine